Sequenom, Inc. (NASDAQ:SQNM) Investor Investigation Over Potential Wrongdoing In Acquisition Announced

If you purchased shares of Sequenom, Inc. (NASDAQ:SQNM) and currently hold any of those NASDAQ:SQNM shares, you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Sequenom
Affected Securities: 
NASDAQ: SQNM

July 29, 2016 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Sequenom, Inc. (NASDAQ:SQNM), was announced concerning whether the takeover of Sequenom, Inc. by Laboratory Corporation of America Holdings for $2.40 per share is unfair to NASDAQ:SQNM stockholders.

The investigation by a law firm concerns whether certain officers and directors of Sequenom, Inc. (NASDAQ:SQNM breached their fiduciary duties owed to NASDAQ:SQNM investors in connection with the proposed acquisition.

On July 27, 2016, Laboratory Corporation of America Holdings and Sequenom, Inc. (NASDAQ:SQNM) announced that they have entered into an agreement and plan of merger under which Laboratory Corporation of America Holdings would acquire all of the outstanding shares of Sequenom in a cash tender offer for $2.40 per share, or an equity value of $302 million, which represents a total enterprise value of approximately $371 million, including net indebtedness.

However, given that in 2015 NASDAQ:SQNM shares reached $4.59 per share, the investigation concerns whether the offer is unfair to NASDAQ:SQNM stockholders. More specifically, the investigation concerns whether the Sequenom Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.